Last reviewed · How we verify
NCT05493267
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Phase 4 trial testing Vγ2Vδ2 T lymphocyte-based immunotherapy in MDR-TB in 30 participants. Currently enrolling.
3 August 2025
Quick facts
| Lead sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 3 August 2022 |
| Primary completion | 3 August 2025 |
| Estimated completion | 3 August 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Vγ2Vδ2 T lymphocyte-based immunotherapy — full drug profile →
- Treatment regimens for MDR-TB — full drug profile →
Conditions studied
- MDR-TB — all drugs for MDR-TB →
- Immunotherapy — all drugs for Immunotherapy →
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Who can join
Adults 18 to 65, any sex, with MDR-TB or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in host-directed therapy for tuberculosis and HIV coinfection: enhancing immune responses.
Prasanna P, Herrera B, Schlesinger LS, Paiardini M, et al · · 2025 · cited 3× · PMID 40345900 · DOI 10.1016/j.tim.2025.04.006
Verify or expand the search:
- PubMed search for NCT05493267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Pulmonary Hospital, Shanghai, China trials
Trials by the same sponsor.
- NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
- NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
- NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
- NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
- NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05493267 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
- Last refreshed: 10 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05493267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing